Neoadjuvant and Adjuvant Treatment in Early-Stage NSCLC: Options Are Expanding – An In the Clinic Activity
Released On
October 12, 2022
Expires On
October 12, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topic(s)
Lung Cancer, Oncology
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Integrity Continuing Education, Inc.
This activity is supported by an educational grant from Merck Sharp & Dohme LLC.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists and other clinicians who treat and manage patients with lung cancer.
Program Overview
The introduction of immune checkpoint inhibitors (ICIs) into the treatment of non-small cell lung cancer (NSCLC) has changed the treatment paradigm and become the standard of care in advanced stage lung cancer. Recent and ongoing efforts to replicate the remarkable success of immunotherapy with ICIs and biomarker-guided targeted therapy in advanced/metastatic NSCLC to the management of early-stage NSCLC have broken through the lull in the therapeutic landscape in this setting. The ICIs atezolizumab, durvalumab, and nivolumab have gained FDA approval for early-stage NSCLC indications. These additions to the treatment toolbox offer opportunities to delay recurrence and improve clinical outcomes for patients with this challenging malignancy.
Hear Drs. Gainor and Sands discuss their approach to these patients in this interactive video presentation that will focus on improving the utilization of immunotherapy for neoadjuvant and adjuvant treatment, including:
- Factors to consider – staging, molecular testing, patient-related factors, and treatment-related factors
- Principles of patient selection – who can/should and cannot/should not be considered for immunotherapy
- Referring patients to immunotherapy clinical trials
- Managing immunotherapy-associated toxicities
- Review of ongoing clinical trials
Learning Objectives
Upon completion of this activity, participants should be able to:
- Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors
- Integrate testing strategies into the treatment planning process for patients with early-stage disease
- Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice
Faculty
Co-Chairs:
.jpg)
Justin F. Gainor, MD
Associate Professor of Medicine
Harvard Medical School
Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Termeer Center for Targeted Therapies
Boston, Massachusetts
Jacob M. Sands, MD
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Instructor of Medicine
Harvard Medical School
Boston, Massachusetts
Case Development Faculty:
Catherine Meador, MD, PhD
Attending Physician, Center for Thoracic Cancers
Instructor of Medicine
Harvard Medical School
Boston, Massachusetts
Physician Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Justin F. Gainor, MD, has reported no financial relationships or relationships to products or devices with ineligible companies.
Catherine Meador, MD, PhD , has reported no financial relationships or relationships to products or devices with ineligible companies.
- Jacob M. Sands, MD
-
- Consultant: AstraZeneca, Daiichi-Sankyo, Jazz Pharmaceuticals, Medtronic, PharmaMar, Sanofi, Takeda
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of October 12, 2022 through October 12, 2023 participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.